24 October, 2019
RALEIGH, North Carolina, October 24, 2019 - The global market for patient engagement has shown a potential of 81 percent improvement in chronic disease management with the support of technology, according to Beroe Inc., a procurement intelligence firm. Biometric measurement devices have shown to be the most useful in patient engagement at a rate of 85 percent. Patient engagement tools allow for better predictive analytics around patient health and more timely intervention thus avoiding the cost of emergency room visits and hospitalizations.
In most countries, patients have little consumer choice in the frequency and type of medicines to take as mostly, doctors make the decisions. The vast majority of patients do not switch brands if the prescribed therapy yields satisfactory results, therefore the initial choice of the drug is crucial. Branded drug manufacturers focus marketing efforts on physicians: their sales representatives discuss product claims and clinical evidence and often distribute samples. According to a study by the European Commission, the continuous growth of perindopril's patient base is due to the existence of the growing group of loyal doctors
Beroe, which is based in North Carolina, further stated that procurement experts can access this report on its recently launched market intelligence platform Beroe LiVE: live.beroeinc.com
Technologies that are patient-centric are found to be most effective in patient engagement as they support patients in efforts to be healthy and provide input to providers on how patients are doing when not in the clinic. Interactive voice response calls, emails, texts, letters, mobile app medication reminders, and one-on-one pharmacist outreach and consultation are being adopted to aid patient adherence. Reasons for abandonment in patient engagement include Health care team/health system-related factors such as lack of knowledge and training in treatment management and/or an inadequate understanding of the disease.
Use cases of technology tools for patient engagement can be improved by focusing on technologies that provide better integration between technology and organizational engagement strategies, allow tighter integration with clinical workflows, are easier-to-use. Future areas of focus for patient engagement technology companies are easier to use products (50 percent), integration with clinical workflows (50 percent), more effective products (28 percent), promote value to patients (27 percent), promote value proposition to payers (26 percent), and lower-cost products for 21 percent.
The research methodology adopted for the report included:
Patient access suppliers are shifting their focus to improve efficiency in problem-solving, and to be multi-specialty and multi-national organizations. Suppliers are trying to become a one-stop-shop service provider by various collaborations and partnerships. Pharmaceutical and biotechnology companies are currently leveraging AI solutions for chronic disease management in the areas of cancer and diabetes. The current machine learning initiatives of the top biopharmaceutical companies show their growing interest in mobile coaching solutions, personalized medicine, and the adoption of technologies for drug discovery purposes.
The report also includes:
Beroe is the world's leading provider of procurement intelligence and supplier compliance solutions. We provide critical market information and analysis that enables companies to make smart sourcing decisions—leading to lower costs, greater profits and reduced risk. Beroe has been providing these services for more than 13 years and currently works with more than 10,000 companies worldwide, including 400 of the Fortune 500 companies.
To learn more about Beroe Inc., please visit: http://www.beroeinc.com
Product Demo: Minimize Risk, Maximize Opportunity with Beroe LiVE.Ai, 8 September